Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.
From the docket
George E. Johnson's Johnson Products launches Ultra Sheen, the first commercially marketed sodium hydroxide-based hair relaxer targeting Black women. The product launches an industry that will grow to nearly $1 billion.
Judge Rowland conducts a Science Day, receiving non-adversarial scientific presentations from both sides. Daubert hearings on general causation experts are scheduled for April–June 2026, with bellwether trials expected in 2027.
The Federal Trade Commission orders Johnson Products to add warning labels to lye-based relaxers following consumer complaints of severe scalp burns and hair damage. This is the first regulatory action targeting hair relaxer safety.
Johnson Products introduces Gentle Treatment, the first commercial no-lye relaxer using guanidine carbonate. While marketed as gentler, no-lye relaxers still contain EDCs including parabens, phthalates, and formaldehyde-releasing agents.
James-Todd et al. publish testing data finding 45 endocrine-disrupting chemicals in hair products — with 84% NOT disclosed on product labels. Cyclosiloxanes, parabens, and phthalates detected at highest concentrations.
White et al. publish findings from the NIEHS Sister Study in Carcinogenesis showing that frequent hair straightener use is associated with a 2.19x increased risk of ovarian cancer.
Chang et al. publish the landmark JNCI study showing frequent hair straightener use doubles uterine cancer risk (HR 2.55). The findings generate widespread media coverage and trigger hundreds of lawsuits within weeks.
The Judicial Panel on Multidistrict Litigation consolidates all federal hair relaxer cancer lawsuits into MDL 3060 under Judge Mary M. Rowland in the Northern District of Illinois (Chicago).
The FDA proposes its first rule directly targeting hair relaxer ingredients — a ban on formaldehyde and formaldehyde-releasing chemicals. The rule has not been finalized despite multiple missed deadlines.
Bertrand et al. publish findings from the first large-scale study entirely within a Black women cohort (44,798 participants), confirming >50% increased uterine cancer risk among long-term relaxer users.
Google Trends data detected a 120% week-over-week increase in searches for 'relaxer and cancer' as of June 24, 2026. The spike was flagged through monitoring of the broader 'hair relaxer lawsuit' search term, suggesting rising public awareness of litigation tied to hair relaxer products.
Google Trends data detected a 120% week-over-week rise in searches for 'relaxer and cancer' as of June 24, 2026. The spike was flagged through monitoring of the broader 'hair relaxer lawsuit' search topic, suggesting growing public awareness of litigation tied to hair relaxer products.
Case results
Johnson & Johnson established a $6.5 billion settlement trust to resolve approximately 60,000 talcum powder ovarian cancer claims. The parallel is direct: a consumer product marketed to women (disproportionately women of color), containing undisclosed carcinogens, causing reproductive cancers through chronic exposure.
Bayer/Monsanto reached a $10.9 billion settlement for Roundup glyphosate cancer claims — approximately $165,000 per claimant for the ~66,000 resolved cases. Demonstrates precedent for massive global settlements when epidemiological evidence links a consumer product to cancer.
The Camp Lejeune Justice Act established a $21 billion settlement framework for approximately 500,000 claimants exposed to toxic water. Like hair relaxers, the case involved chronic exposure to endocrine disruptors and carcinogens through a trusted institution, with disproportionate impact on vulnerable populations.
Stay informed
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Full case details
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View the full Hair Relaxer Cancer case page →